|
業務類別
|
Biotechnology |
|
業務概覽
|
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. |
| 公司地址
| 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021 |
| 電話號碼
| +1 210 974-6900 |
| 傳真號碼
| +1 210 974-6901 |
| 公司網頁
| https://www.cerenome.com |
| 員工數量
| 28 |
| Dr. Marc H. Hedrick,M.D. |
Chief Executive Officer, President and Director |
美元 585.00K |
09/04/2026 |
| Mr. Andrew Sims |
Chief Financial Officer and Principal Accounting Officer |
美元 390.00K |
31/03/2026 |
| Dr. Eric J. Daniels |
Chief Development Officer |
-- |
09/04/2026 |
|
|
| Dr. Marc H. Hedrick,M.D. |
Chief Executive Officer, President and Director |
09/04/2026 |
| Mr. Ronald A. Andrews, Jr |
Independent Director |
26/03/2026 |
| Mr. Richard J. Hawkins |
Chairman of the Board |
31/03/2026 |
| Mr. Kyle Guse, C.P.A.,M.B.A. |
Independent Director |
31/03/2026 |
| Dr. An van Es-Johansson, M.D. |
Independent Director |
31/03/2026 |
| Mr. Howard Clowes |
Independent Director |
31/03/2026 |
|
|
|
|
